Janus kinase-1 and 3 in ankylosing spondylitis

Hsien Tzung Liao, Tzu Hao Li, Chun Hsiung Chen, Hung An Chen, Wei Sheng Chen, Chien Chih Lai, Chung Tei Chou, Chang Youh Tsai

研究成果: 雜誌貢獻文章同行評審

2 引文 斯高帕斯(Scopus)


Background/purpose: To investigate the Janus kinase-1 and 3 (JAK-1 and 3) expression in peripheral blood mononuclear cells (PBMCs) in ankylosing spondylitis (AS). Methods: The levels of JAK-1 and JAK-3 mRNA in PBMCs, CD3 + T cells and CD14 + monocytes were measured by RT-PCR in 52 AS patients and 31 healthy controls (HCs). The demographic features, BASDAI, BASFI, HLA-B27, ESR, CRP and serum immunoglobulin A (IgA) level were recorded and correlated with the JAK-1 & JAK-3 transcripts in patients and HCs as appropriate. Results: JAK-1 and JAK-3 expression in PB CD3 + T cells plus CD14 + monocytes was significantly higher in AS patients than in HCs (p < 0.05). There is a positive correlation between JAK-1 expression in CD3 + T cells plus CD14 + monocytes and ESR, CRP, IgA, HLA-B27, peripheral arthritis, enthesitis and uveitis (all p < 0.05), respectively. JAK-1 transcript was also increased in CD14 + monocytes from patients and correlated well with ESR and CRP as the disease deteriorated. Conversely, JAK-1 was negatively correlated to chest expansion. Area under the curve of standard receiver operating characteristic suggested that JAK-1 transcript in CD3 + T cells plus CD14 + monocytes is better to predict the higher BASDAI (>4) and BASFI (>4) than ESR or CRP in AS patients. Conclusion: In AS, JAK-1 expression in PB cells rather than ESR or CRP might be regarded as a bio-marker for monitoring disease activity and functional index in AS. These findings have also suggested that JAK-1 and JAK-3 expression may play a role in the inflammatory processes in patients with AS.

頁(從 - 到)134-141
期刊Journal of the Formosan Medical Association
出版狀態已發佈 - 1月 2019

ASJC Scopus subject areas

  • 醫藥 (全部)


深入研究「Janus kinase-1 and 3 in ankylosing spondylitis」主題。共同形成了獨特的指紋。